Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-535-4
CAS number: 84-51-5
No ADME and dermal absorption study with the
test substance are available. However, a series of acute and repeated
dose toxicity studies give an indication about the bioavailability after
oral and dermal application. In acute and repeated dose oral toxicity
studies with 2-ethylanthraquinone systemic toxicity was seen leading to
the conclusion that the test substance is bioavailable after oral
application. There are also indications that the yellow coloured test
substance is excreted with the urine, since in two repeated dose oral
toxicity studies a dose related increase in the intensity of
yellow-amber coloured urine is described.
After dermal application of 20 g test
substance/kg bw in a acute dermal toxicity test and dermal application
in a Local Lymph Node Assay, no systemic effects could be observed. This
could indicate that the dermal absorption of 2-ethylanthraquinone is
low. Furthermore the high octanol/water partition coefficient (log Pow =
4.6) of the substance could result in a low skin penetration.
Due to the very low vapour pressure (1.2 x
10^-4 Pa at 25C°) inhalation exposure is only possible via aerosols of
solid particles or dissolved material. It is assumed that the substance
is bioavailable via the lungs.
The systemic effects (mainly changes in the
hematopoiesis) indicate that the substance is distributed throughout the
body after oral absorption. Due to the low water solubility and the high
octanol/water partition coefficient accumulation in fatty tissues could
The finding that urine was coloured
amber-yellow in repeated dose studies might support the conclusion that
some amounts of the substance are not metabolised and excreted unchanged
via urine. Due to the low water solubility excretion via the bile is
- accumulation in fatty tissues could occur,
- bioavailable after oral application,
- indications that test substance is excreted with urine,
- dermal absorption expected to be low,
- bioavailability via the lungs is assumed.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again